Genome Engineering of Primary Human B Cells Using CRISPR/Cas9
November 3rd, 2020
6.1K views
Here we provide a detailed, step-by-step protocol for CRISPR/Cas9-based genome engineering of primary human B cells for gene knockout (KO) and knock-in (KI) to study biological functions of genes in B cells and the development of B-cell therapeutics.
Overview
This study presents a detailed protocol for CRISPR/Cas9-based genome engineering in primary human B cells, enabling gene knockout and knock-in to explore gene functions and develop B-cell therapeutics.
Key Study Components
Research Area
- Genomics
- Cell Biology
- Therapeutic Development
Background
- Importance of studying gene function in B cells
- CRISPR/Cas9 technology enabling precise edits
- Potential applications in infectious disease and enzymopathies
Methods Used
- CRISPR/Cas9 transfection of primary B cells
- Primary human B cells as the biological model
- Electroporation for delivering gene editing tools
Main Results
- Successful knockout of the CD19 gene with over 95% reduction in expression
- High rates of indel formation at the CD19 locus confirmed by genomic sequencing
- Capable of introducing transgenes and editing base pairs for functional studies
Conclusions
- This protocol effectively enhances the study of B-cell biology and therapeutics.
- It provides a robust platform for gene editing, with significant implications for medical research.
Frequently Asked Questions
What is the main advantage of this CRISPR/Cas9 method for B cells?
It offers a universal platform for high-efficiency gene editing in primary human B cells.
How is the CRISPR/Cas9 transfection performed?
The method involves thawing B cells, preparing the CRISPR components, and using electroporation for cell transfection.
What are the potential applications of this method?
It can be used for creating recombinant antibodies, gene therapies, and studying gene functions associated with diseases.
How are successful genome edits confirmed?
Genomic sequencing and flow cytometry analyses are used to validate the knockout and knock-in results.
Can this method be used for research beyond B cells?
While this study focuses on B cells, the underlying techniques can potentially be adapted for other cell types.
What does the study reveal about gene editing efficiency?
High editing efficiency was demonstrated, with significant reductions in gene expression reported.
Are there limitations to this CRISPR/Cas9 protocol?
Cell recovery can vary based on the editing process, but most samples rebound quickly after engineering.
Executive Industry Relevance
This protocol enables precise genome engineering of primary human B cells using CRISPR/Cas9, supporting target validation and therapeutic protein expression. It provides a scalable platform for developing B-cell-based therapeutics for infectious diseases and enzymopathies. The method enhances predictive confidence in gene function studies and de-risks translational advancement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional interrogation of gene loss-of-function effects in primary human B cells.
- Operational Value: Supports efficient knockout of endogenous genes to clarify biological pathways and mechanisms.
- Strategic Value: Facilitates target de-risking by validating gene essentiality in a disease-relevant immune cell model.
Screening & Assay Development
- Scientific Value: Generates engineered B cells with stable transgene expression for consistent functional readouts.
- Operational Value: Enables production of recombinant antibodies or enzymes at scale for downstream screening applications.
- Strategic Value: Provides a renewable cellular system for assay development targeting humoral immune responses.
Translational & Preclinical Research
- Scientific Value: Supports preclinical evaluation of B-cell therapeutics through stable transgene integration and expression.
- Operational Value: Demonstrates recovery kinetics post-engineering, informing dosing and manufacturing timelines.
- Strategic Value: Enables risk-adjusted advancement by linking gene edits to functional outcomes in a clinically relevant cell type.
Pipeline & Workflow Integration
The method integrates into early discovery for target validation, progresses to lead identification via transgene expression, and supports preclinical work through functional B-cell engineering.
- Discovery Biology: Enables hypothesis testing via knockout of genes of interest in primary human B cells.
- Screening: Produces standardized, expandable B-cell populations for consistent compound or antigen evaluation.
- Analytics: Delivers quantitative outputs including flow cytometry, genomic sequencing, and junction PCR for edit validation.
- Translational Research: Connects gene editing to therapeutic potential through recombinant antibody or enzyme expression.
- Enterprise Reuse: Establishes a reusable platform for iterative gene editing across multiple targets in B-cell therapeutics.
Operational & Enterprise Impact
- Scientific Value: High editing efficiency with over 95% CD19 knockout and 64% knock-in rates, enabling reliable mechanistic studies.
- Operational Value: Electroporation-based delivery ensures reproducibility and scalability across transfection reactions.
- Strategic Value: Reduces reliance on complex gene engineering approaches, lowering development timelines and costs.
- Portfolio Impact: Supports go/no-go decisions by providing functional data on gene essentiality and therapeutic protein yield.
Implementation Considerations
- Requires expertise in primary cell handling, electroporation, and CRISPR/Cas9 reagent preparation.
- Dependent on access to electroporators, transfection reagents, and rAAV vector production infrastructure.
- Necessitates standardized protocols for B-cell isolation, expansion, and medium equilibration across teams.
- Requires adaptation considerations for different gene targets or transgene cassettes in primary B cells.
- Practical limitations include variable cell recovery post-engineering, though samples typically rebound within three days.
Biopharma FAQs
Why is CD19 knockout efficiency measured by flow cytometry?
Flow cytometry quantifies CD19-negative cell populations to validate loss-of-function editing, with 95% reduction observed in knockout samples. This provides a direct, quantitative readout of protein-level changes post-CRISPR/Cas9 editing. The method enables comparison between control and edited populations to confirm target engagement.
How does rAAV6 multiplicity of infection affect transgene integration?
A multiplicity of infection of 500,000 rAAV6 vector particles was used to achieve efficient transgene delivery in electroporated B cells. This high MOI supports robust knock-in, resulting in 64% EGFP-positive cells in combined CRISPR/Cas9 and rAAV6 conditions. The approach enables stable transgene expression for therapeutic protein production.
What genomic sequencing outputs confirm CRISPR/Cas9 editing?
Genomic sequencing chromatograms show double peaks at the CD19 locus, indicating insertions or deletions following double-stranded breaks. Indel analysis confirms high rates of mutation formation, correlating with flow cytometry-detected protein loss. These outputs provide molecular validation of gene editing efficiency and specificity.
Why is junction PCR used in knock-in validation?
Junction PCR amplifies a 1.5 kb amplicon only when successful transgene integration occurs via homologous recombination. No product is observed in control or vector-only samples, confirming specificity of the knock-in event. This assay distinguishes random integration from precise, site-specific cassette insertion.
How do recovery kinetics influence manufacturing timelines?
Although engineering affects cell recovery initially, all samples rebound within three days post-transfection. This rapid recovery supports scalable manufacturing and reduces downtime in therapeutic production workflows. The resilience of engineered B cells enables consistent expansion for downstream applications.
